Technology

The company's drug discovery platform, Quantum Molecular Design ("QMD"), deploys an integrated combination of Artificial Intelligence, advanced quantum chemistry, and cloud computing to rapidly generate high quality drug-like hits and leads for a wide range of drug targets, including demonstrated success on targets previously considered to be "undruggable", at low cost.

The Artificial Intelligence methods used include augmented intelligence, heuristic search, expert systems and machine learning to reduce computational cost and reduce toxic side effects. The company has achieved biological activity and promising preclinical data on 100% of the drug targets it has tested so far, including allosteric targets, protein-protein interaction disruption, nuclear receptors, and drug candidates designed for selectivity.